The Australian medical landscape is buzzing with the introduction of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist showing remarkable results in early trials for treating obesity. This https://johsocial.com/story12460212/retatrutide-australia-australia-a-emerging-hope-for-weight-loss